Authors: Rustin, GJS Marples, M Nelstrop, AE Mahmoudi, M Meyer, T

Citation: Gjs. Rustin et al., Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels, J CL ONCOL, 19(20), 2001, pp. 4054-4057

Authors: Rustin, GJS Nelstrop, AE Bentzen, SM Bond, SJ McClean, P

Citation: Gjs. Rustin et al., Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials, J CL ONCOL, 18(8), 2000, pp. 1733-1739

Authors: Tuxen, MK Soletormos, G Rustin, GJS Nelstrop, AE Dombernowsky, P

Citation: Mk. Tuxen et al., Biological variation and analytical imprecision of CA 125 in patients withovarian cancer, SC J CL INV, 60(8), 2000, pp. 713-721

Authors: Lee, CK de Miranda, MP Ledermann, JA de Elvira, MCR Nelstrop, AE Lambert, HE Rustin, GJS Trask, CWL

Citation: Ck. Lee et al., Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy, EUR J CANC, 35(5), 1999, pp. 727-732

Authors: Rustin, GJS Nelstrop, AE Bentzen, SM Piccart, MJ Bertelsen, K

Citation: Gjs. Rustin et al., Use of tumour markers in monitoring the course of ovarian cancer, ANN ONCOL, 10, 1999, pp. 21-27

Authors: Bridgewater, JA Nelstrop, AE Rustin, GJS Gore, ME McGuire, WP Hoskins, WJ

Citation: Ja. Bridgewater et al., Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel, J CL ONCOL, 17(2), 1999, pp. 501-508